Released on = May 30, 2007, 4:01 am

Press Release Author = La Merie Business Intelligence

Industry = Biotech

Press Release Summary = The antithrombotics market with the two blockbusters
enoxaparin and prasugrel is challenged by generic products as well as by next
generation anticoagulants with oral administration and antithrombotics with an
improved risk-benefit ratio

Press Release Body = BARCELONA, Spain | May 30, 2007 | The Business Intelligence
firm La Merie S.L. reported today that the US$ 9.6 bln market of the two blockbuster
antithrombotic agents enoxaparin and clopidogrel is going to be rearranged by loss
of patent protection and emergence of phase III stage competitors with improved
profiles. While Bristol-Myers Squibb already suffers from dropping sales (US$ 3.3
bln in 2006 for prasugrel), Sanofi-Aventis will be affected stronger in its ex-US
sales of prasugrel (US$ 3 bln) and global sales of enoxaparin (3.3 bln).
Sanofi-aventis has the biggest anticoagulant pipeline by numbers, but does not lead
the next generation of oral thrombin (factor IIa) and factor Xa inhibitors which
have the potential to replace parenteral product enoxaparin, a low molecular weight
heparin (LMWH). At least seven clinical stage direct thrombin inhibitors and at
least 10 clinical stage direct factor Xa inhibitors are in the anticoagulant
pipeline lead by Boehringer Ingelheim and Bayer Schering Pharma. Despite the larger
market of the antiplatelet agent prasugrel, the number of advanced clinical stage
antiplatelet projects is smaller than that of anticoagulants. These results and more
were found in a competitor analysis conducted by La Merie Business Intelligence. The
competitor analysis of Antithrombotics can be acquired at www.pipelinereview.com, La
Merie's News Center and Online Store.

The competitor analysis evaluated anticoagulant and antiplatelet agents in
development. Apart from the oral direct factor IIa and Xa inhibitors, oral heparin
and oral LMWH developments are ongoing and novel targets being explored in
preclinical and clinical trials. Further companies with a strong antithrombotics
portfolio include Daiichi-Sankyo, AstraZeneca and Organon & Schering-Plough. The
convenience of oral administration will be the most obvious advante of the next
generation anticoagulants, but the reduced incidence of thrombotic events and of
bleeding side effects key to the commercial success under the light of the imminent
approval of the first enoxaparin generics.

About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high
quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals. For more
information visit www.lamerie.com.
About PipelineReview.com
Pipelinereview.com is the News Center and Online Store of La Merie Business
Intelligence focused on Research and Development in the Biopharmaceutical Industry.
Visitors of PipelineReview.com will find R&D relevant press releases and can receive
selected R&D news from one or more of the site's News Channels. A free R&D Newletter
conveniently brings via e-mail a daily selection of the most interesting news from
biopharmaceutical R&D. For more information visit pipelinereview.com


Web Site = http://www.pipelinereview.com/joomla/content/view/12062/109/

Contact Details = Pau Cuevas
C/Casp 33 B 4º 2ª.
08010 Barcelona
Tel + 34 93 342 91 97
Fax + 93 342 91 98
eMail: Pau.cuevas@lamerie.com
Online Store: www.pipelinereview.com.
http://www.lamerie.com